Salute e Benessere

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course…

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value CreationNANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)reaffirms its strategic commitment to value creation ahead of the September 30 Annual General Meeting. The Company is focused on developing innovative therapies in immuno-oncology and immuno-inflammation, supported by a robust and differentiated portfolio, a cutting-edge research...
Nasdaq GlobeNewswire
04/09/2025

Fertility Supplements Market Size Projected to Reach US$ 4.74 Billion by 2033…

Global players like Fairhaven Health have built trusted product lines including Fertilaid and OvaBoost, while newer entrants such as Natalist and Bird&Be are reshaping the space with clean-label, personalized capsule packs that resonate with millennial consumers. Meanwhile, e-commerce and subscription-based DTC models are reshaping how these products reach consumers, offering discreet, convenient access paired with fertility tracking tools and educational content. With healthcare…
PR Newswire
04/09/2025

BASTIDE : 2024-2025 revenue target met // 2024-2025 revenue from continuing…

Caissargues, September 4, 2025 Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no longer includes revenue from subsidiaries sold or in the process of being sold (CICA Plus, Medsoft, Cicadum, Dyna Médical, Dorge and Baywater)…
Actusnews Wire
04/09/2025

MSC-Specific Cell Culture Medium Market to Reach USD 4.1 Billion by 2035, with…

MSC culture media provide the essential nutrients, growth factors, and optimized formulations required to expand MSCs while maintaining their multipotency and therapeutic potential. Their application is growing rapidly across drug discovery, cancer research, regenerative medicine, and cell therapy. MSC culture media provide the essential nutrients, growth factors, and optimized formulations required to expand MSCs while maintaining their multipotency and therapeutic potential. Their…
PR Newswire
04/09/2025

RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033…

Advances in delivery technologies, particularly GalNAc conjugates for hepatocyte targeting and lipid nanoparticles (LNPs), have further amplified RNAi's market potential by improving safety, durability, and patient convenience. Strategic partnerships between RNAi innovators and global pharma leaders are accelerating commercialization and broadening clinical pipelines, while regulatory agencies are offering supportive pathways such as orphan drug and breakthrough designations. RNAi is no longer…
PR Newswire
04/09/2025

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the…

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 thAnnual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now availablehere Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program OCALA, Fla., Sept.04, 2025(GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(NYSE...
Nasdaq GlobeNewswire
04/09/2025

Oxygen Concentrators Market worth US$1.71 billion by 2030 with 6.1% CAGR |…

Browse in-depth TOC on "Oxygen Concentrators Market" Browse in-depth TOC on "Oxygen Concentrators Market" 354 - Tables 51 - Figures 245 - Pages By type,the market for OC is divided into portable oxygen concentrators and stationary oxygen concentrators. In 2024, the portable oxygen concentrator segment holds the largest share of the global oxygen concentrators market. The portable oxygen concentrators (POC) segment is expected to dominate the market due to increasing demand...
PR Newswire
04/09/2025

PridCor Therapeutics Reports Positive Long COVID Case Series with Combination…

-New Preprint:PridCor Therapeutics LLC has released a pre-print detailing a case series of 15 patients with Long COVID (LC) who were given a continuous regimen of 120-days of valacyclovir and celecoxib with a pulsed 15-day treatment of Paxlovid (combination antiviral treatment, or CAR), and these patients were compared to 12 patients with Long COVID who received the 120-day valacyclovir and celecoxib protocol only. This CAR appeared superior to the valacyclovir and celecoxib combination in...
Nasdaq GlobeNewswire
04/09/2025

Olympus Announces Distribution Partnership with MacroLux Medical for Single-Use…

"We are excited to embark on this new partnership, a synergy that underscores our unwavering commitment to advancing patient care," said Gabriel McHugh, Executive Vice President Surgical and Interventional Solutions, Olympus Corp. "By integrating innovative single-use technology into our urology portfolio, we are enhancing the landscape of urological care for our customers and their patients." "We are excited to embark on this new partnership, a synergy that underscores…
PR Newswire
04/09/2025

AI in Nutraceuticals Market Hits $2.48 Billion in 2032, Set to Transform…

The Dawn of Predictive and Adaptive Nutraceutical Solutions The Dawn of Predictive and Adaptive Nutraceutical Solutions AI is transforming thenutraceutical industrywith advances in machine learning, predictive analytics, computer vision, and natural language processing. These technologies streamline R&D pipelines-driving faster product formulation, real-time quality assurance, and supply chain transparency. From optimizing extraction techniques to enabling traceability through...
PR Newswire
04/09/2025

Dental Consumables Market worth US$66.94 billion by 2030 with 8.5% CAGR |…

Browse in-depth TOC on "Dental Consumables Market" Browse in-depth TOC on "Dental Consumables Market" 749 - Tables 57- Figures 555 - Pages By product type,the market is segmented into dental restoration, orthodontics, periodontics, infection control, endodontics, whitening products, finishing & polishing products, and other dental consumables. The rising prevalence of dental caries and tooth decay has increased demand for restorative materials like composites…
PR Newswire
04/09/2025

Govee Leads Smart Lighting Evolution with Industry-First Innovations at IFA 2025

Govee's latest products embody the brand's philosophy, "Life is Colorful," empowering users to personalize their homes with lighting that combines aesthetic appeal and practical functionality. By moving beyond mere convenience, Govee's innovative solutions are designed to enrich daily living, creating spaces that feel calming, expressive, and emotionally nurturing – truly reflecting individual style and enhancing well-being. Govee's latest products embody the brand's philosophy…
PR Newswire
04/09/2025

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan…

REYKJAVIK, Iceland, June 4, 2025- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat...
Nasdaq GlobeNewswire
04/09/2025

MedTech Industry Powerhouses Join Forces to Launch HSMG Advisors

With more than a century of combined experience, the principals bring deep expertise across four core pillars essential to MedTech leadership: Withmore than a century of combined experience, the principals bring deep expertise across four core pillars essential to MedTech leadership: The founding principals, Bernie Haffey , Glenn Snyder and Joe Mullings are widely respected operators and advisors who have each shaped the trajectory of industry-leading companies. Together, they...
PR Newswire
04/09/2025

Laifen to Launch Two Innovative Electric Razors T1 Pro and P3 Pro at IFA 2025

"With the T1 Pro and P3 Pro, we are consistently continuing our design philosophy: precise technology, high-quality materials, and genuine everyday practicality. Both models exemplify our commitment to making technology accessible to everyone – without compromising on performance or quality," says Hongxin Ye, founder and CEO at Laifen. "With the T1 Pro and P3 Pro, we are consistently continuing our design philosophy: precise technology, high-quality materials, and genuine everyday…
PR Newswire
04/09/2025

One2Treat raises capital to further accelerate software platform development and…

Shareholder confidence accelerates One2Treat's investment in software platform development. Shareholder confidence accelerates One2Treat's investment in software platform development. The conclusion of One2Treat's planned seed extension funding round marks a key milestone in the company's growth. This investment follows the successful deployment of the One2Treat Insights ®module across multiple live projects and the recent release of the One2Treat Voice ®module. It reflects the...
PR Newswire
04/09/2025

Bioretec Appoints Dr. Christopher W. DiGiovanni to Scientific Advisory Board

Dr. DiGiovanni is an internationally recognized foot and ankle surgeon who has dedicated nearly three decades to advancing clinical care, surgical innovation, and medical education. He currently serves as Professor of Orthopaedic Surgery at Harvard Medical School in the Department of Orthopaedic Surgery and Chief Emeritus of Foot and Ankle Services at Massachusetts General Hospital (MGH) / Newton-Wellesley Foot & Ankle Center. He is a Past President of both the American Orthopaedic Foot and…
PR Newswire
04/09/2025

MolecuLight Showcases 10 Scientific Posters at SAWC Fall and Announces Upcoming…

MolecuLight is advancing its technology by expanding the MolecuLightDX®+ imaging platform to include oxygenation imaging—delivering all vital wound care imaging in one compact, fully handheld system that maximizes clinician time and documentation, with FDA submission expected Q4 2025. This new capability will allow clinicians to assess oxygenation, detect bacterial burden, accurately measure wounds, and see thermal changes from a single device—eliminating the need to rely on multiple…
PR Newswire
04/09/2025

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global…

About Halia Therapeutics About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies. Halia's mission is to create data-driven therapies...
PR Newswire
04/09/2025

Sentec Receives FDA Clearance for LuMon™ Electrical Impedance Tomography (EIT)…

The LuMon™ EIT System delivers functional lung imaging directly at the bedside—without radiation—helping clinicians better tailor therapy to each patient's unique needs. The LuMon™ EIT System delivers functional lung imaging directly at the bedside—without radiation—helping clinicians better tailor therapy to each patient's unique needs. Clearance for Premature Infant Use Supports NICU Clinicians to Personalize Ventilatory Care While the LuMon™ System can be used to monitor a variety of...
PR Newswire
04/09/2025

Grünenthal PRO is joining SHL Medical's alliance partnership network to offer…

In parallel, SHL customers will benefit from access to Grünenthal PRO's established expertise and capacity in delivering high quality, reliable contract manufacturing services. In parallel, SHL customers will benefit from access to Grünenthal PRO's established expertise and capacity in delivering high quality, reliable contract manufacturing services. "Speed-to-market is a decisive advantage in today's biopharma landscape," saysVictor Barbosa, Executive Vice President of Global…
PR Newswire
04/09/2025

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash…

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash RunwayStrategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer’s and Parkinson’s diseases and progressing high value candidates enabling intracellular targetingNear term clinical milestones remain unchangedCash resources of CHF 127...
Nasdaq GlobeNewswire
04/09/2025

Blue Cell Therapeutics appoints highly experienced pharma and biotech executive…

Dr Søren P. Sheikh MD, PhD, Chief Executive Officer of Blue Cell Therapeutics, said: "Olav brings a wealth of knowledge and experience that will be instrumental to Blue Cell Therapeutics as we advance. His proven leadership across diverse teams and strategic planning expertise in multiple markets will be a huge asset. We look forward to working closely with Olav and the Board as we advance our lead candidate, BlueC-231, for severe erectile dysfunction into Phase 1/2a clinical trials."…
PR Newswire
04/09/2025

Onco3R Therapeutics Announces Approval of First Clinical Trial Application for…

O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseasesClinical Trial Application approval marks Onco3R’s transition into a clinical-stage companyLeuven, Belgium. September 4, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the approval of a Clinical...
Nasdaq GlobeNewswire
04/09/2025
Altri  Comunicati